Form 8.3 - Abbvie Inc
March 25 2020 - 11:15AM
Dow Jones News
TIDM0QCV TIDM0Y7T
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997,
TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING
1% OR MORE
1. KEY INFORMATION
Name of person dealing (Note 1) State Street Global Advisors &
Affiliates
--------------------------------------------- -------------------------------
Company dealt in AbbVie Inc.
--------------------------------------------- -------------------------------
Class of relevant security to which US$0.01 common stock
the dealings being disclosed relate (Note 2)
--------------------------------------------- -------------------------------
Date of dealing 24(th) March 2020
--------------------------------------------- -------------------------------
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of
relevant security dealt in (Note 3)
Long Short
------------------------------------- -------------------- -----------
Number (%) Number (%)
------------------------------------- ---------- -------- ------ ---
(1) Relevant securities 68,013,859 4.60589%
------------------------------------- ---------- -------- ------ ---
(2) Derivatives (other than options) N/A
------------------------------------- ---------- -------- ------ ---
(3) Options and agreements to
purchase/sell N/A
------------------------------------- ---------- -------- ------ ---
Total 68,013,859 4.60589%
------------------------------------- ---------- -------- ------ ---
(b) Interests and short positions in relevant securities of the company,
other than the class dealt in (Note 3)
Class of relevant security: Long Short
------------------------------------------- ----------- -----------
Number (%) Number (%)
------------------------------------------- ------ --- ------ ---
(1) Relevant securities N/A
------------------------------------------- ------ --- ------ ---
(2) Derivatives (other than options) N/A
------------------------------------------- ------ --- ------ ---
(3) Options and agreements to purchase/sell N/A
------------------------------------------- ------ --- ------ ---
Total N/A
------------------------------------------- ------ --- ------ ---
3. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale Number of relevant securities Price per unit (Note 5)
-------------- ----------------------------- -----------------------
Purchase 6,300 67.49
-------------- ----------------------------- -----------------------
Purchase 9,400 67.49
-------------- ----------------------------- -----------------------
Purchase 58,000 69.28
-------------- ----------------------------- -----------------------
Purchase 17,400 67.49
-------------- ----------------------------- -----------------------
Purchase 400 184.89
-------------- ----------------------------- -----------------------
Purchase 6,800 68.69
-------------- ----------------------------- -----------------------
Purchase 1,000 69.28
-------------- ----------------------------- -----------------------
Purchase 3,900 68.94
-------------- ----------------------------- -----------------------
Purchase 293 67.49
-------------- ----------------------------- -----------------------
Purchase 184,912 67.49
-------------- ----------------------------- -----------------------
Purchase 71,496 67.49
-------------- ----------------------------- -----------------------
Purchase 1,856 67.49
-------------- ----------------------------- -----------------------
Purchase 480 67.49
-------------- ----------------------------- -----------------------
Purchase 3,536 67.49
-------------- ----------------------------- -----------------------
Purchase 2,907 67.49
-------------- ----------------------------- -----------------------
Purchase 534 67.49
-------------- ----------------------------- -----------------------
Purchase 564 67.49
-------------- ----------------------------- -----------------------
Purchase 500 67.49
-------------- ----------------------------- -----------------------
Sale 1,000 67.49
-------------- ----------------------------- -----------------------
Sale 5,079 67.49
-------------- ----------------------------- -----------------------
Sale 500 70.22
-------------- ----------------------------- -----------------------
Sale 400 184.89
-------------- ----------------------------- -----------------------
Sale 200 70.22
-------------- ----------------------------- -----------------------
Sale 88,011 67.49
-------------- ----------------------------- -----------------------
Sale 15,888 67.49
-------------- ----------------------------- -----------------------
Sale 2,500 67.49
-------------- ----------------------------- -----------------------
Sale 10,362 67.49
-------------- ----------------------------- -----------------------
Sale 10,024 67.49
-------------- ----------------------------- -----------------------
Sale 720 67.49
-------------- ----------------------------- -----------------------
Sale 500 69.07
-------------- ----------------------------- -----------------------
Sale 91 67.49
-------------- ----------------------------- -----------------------
Sale 6,000 71.08
-------------- ----------------------------- -----------------------
Sale 3,500 68.57
-------------- ----------------------------- -----------------------
Sale 969 67.49
-------------- ----------------------------- -----------------------
(b) Derivatives transactions (other than options transactions)
Product name, Nature of transaction Number of relevant securities Price per unit
e.g. CFD (Note 6) (Note 7) (Note 5)
------------- --------------------- ----------------------------- --------------
N/A
------------- --------------------- ----------------------------- --------------
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name, Writing, selling, Number of Exercise Type, e.g. Expiry Option money
e.g. call option purchasing securities to which price American, date paid/received
varying etc. the option relates European etc. per unit (Note 5)
(Note 7)
----------------- ----------------- -------------------- -------- -------------- ------ ------------------
N/A
----------------- ----------------- -------------------- -------- -------------- ------ ------------------
(ii) Exercising
Product name, Number of securities Exercise price per
e.g. call option unit (Note 5)
----------------- -------------------- ------------------
N/A
----------------- -------------------- ------------------
(d) Other dealings (including transactions in respect of new securities)
(Note 4)
Nature of transaction Details Price per unit
(Note 8) (if applicable) (Note 5)
--------------------- ------- -------------------------
N/A
--------------------- ------- -------------------------
4. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or
derivatives
Full details of any agreement, arrangement or understanding
between the person disclosing and any other person
relating to the voting rights of any relevant securities
under any option referred to on this form or relating
to the voting rights or future acquisition or disposal
of any relevant securities to which any derivative
referred to on this form is referenced. If none, this
should be stated.
-----------------------------------------------------------
N/A
-----------------------------------------------------------
Is a Supplemental Form 8 attached? (Note 9) NO
------------------------------------------------------- -----------------
Date of disclosure 25(th) March 2020
------------------------------------------------------- -----------------
Contact name Lionel Colaco
------------------------------------------------------- -----------------
Telephone number 020 33956098
------------------------------------------------------- -----------------
If a connected EFM, name of offeree/offeror with which N/A
connected
------------------------------------------------------- -----------------
If a connected EFM, state nature of connection (Note N/A
10)
------------------------------------------------------- -----------------
(END) Dow Jones Newswires
March 25, 2020 11:00 ET (15:00 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Allergan (NYSE:AGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Allergan (NYSE:AGN)
Historical Stock Chart
From Apr 2023 to Apr 2024
